• Optimizing Assays with (-)-Epigallocatechin gallate (EGCG):

  2026-05-29

  This article provides evidence-based answers to common experimental challenges in cell viability, apoptosis, and cytotoxicity assays using (-)-Epigallocatechin gallate (EGCG), referencing SKU A2600 from APExBIO. Drawing on recent literature and validated protocols, it demonstrates how EGCG enhances reproducibility, sensitivity, and workflow efficiency in biomedical research.

• CX-5461: RNA Polymerase I Inhibitor for Solid Tumor Models

  2026-05-29

  CX-5461, a potent RNA polymerase I inhibitor from APExBIO, empowers cancer researchers to dissect ribosome biogenesis and enhance chemotherapeutic sensitivity in solid tumor models. This guide delivers workflow-driven protocols, troubleshooting, and actionable insights, translating recent breakthroughs into practical laboratory applications.

• Mecamylamine Hydrochloride in nAChR Assays: Protocols & Inno

  2026-05-28

  Mecamylamine hydrochloride is a versatile, blood-brain barrier-permeable nAChR antagonist enabling advanced neuropsychiatric disorder research. This article translates new gut-brain axis discoveries into actionable workflows, with troubleshooting tips and comparative insights for robust experimental design.

• Reinventing VEGF Pathway Inhibition: Axitinib as a Translati

  2026-05-28

  This thought-leadership article explores Axitinib (AG 013736) as both a mechanistic probe and a strategic asset for translational cancer researchers. By bridging foundational in vitro assay methodology, nuanced VEGF signaling insights, and practical preclinical guidance, the piece frames Axitinib as a gold standard tool for robust angiogenesis and tumor growth inhibition studies—distinctly advancing the dialogue beyond standard product pages or protocol guides.

• Troglitazone: PPARγ Agonist for Metabolic and Tumor Research

  2026-05-27

  Troglitazone is a synthetic, selective PPARγ agonist used in type 2 diabetes research and emerging anti-tumor studies. It modulates lipid and glucose metabolism and demonstrates apoptosis-inducing effects in renal carcinoma cells. APExBIO supplies Troglitazone at high purity for research applications.

• G007-LK Tankyrase 1/2 Inhibitor: Precision Targeting in APC-

  2026-05-27

  Explore the scientific depth and research applications of the G007-LK tankyrase 1/2 inhibitor in APC mutation colorectal cancer models. This article uniquely dissects mechanistic insights and practical assay guidance for Wnt/β-catenin pathway inhibition.

• Deferoxamine Mesylate: Iron-Chelating Agent for Advanced Res

  2026-05-26

  Deferoxamine mesylate empowers researchers to precisely manipulate iron metabolism, oxidative stress, and hypoxia signaling in complex disease models. This guide demystifies experimental workflows, highlights troubleshooting nuances, and translates recent advances—such as the integration of ferroptosis modulation—into practical laboratory strategies.

• Viral-Induced RIPK3 Degradation Regulates Necroptosis and In

  2026-05-26

  Liu et al. (2021) uncovered a novel viral mechanism by which orthopoxviruses induce ubiquitin-proteasome-dependent degradation of the necroptosis adaptor RIPK3, thereby modulating virus-induced inflammation and pathogenesis. This discovery advances our understanding of viral immune evasion and highlights the utility of proteasome inhibitors in dissecting host-pathogen interactions.

• Chloroquine for Research: Protocols, Applications & Troubles

  2026-05-25

  Chloroquine (N4-(7-chloroquinolin-4-yl)-N1,N1-diethylpentane-1,4-diamine) stands out as an autophagy and Toll-like receptor inhibitor with proven versatility in malaria, rheumatoid arthritis, and cancer research. This article delivers actionable protocols, advanced use-cases, and expert troubleshooting advice to empower robust, reproducible results with APExBIO’s research-grade Chloroquine.

• 4-Phenylbutyric Acid: Bridging ER Stress Pathways and Cell F

  2026-05-25

  Discover how 4-Phenylbutyric acid (4-PBA) uniquely modulates endoplasmic reticulum stress and cell fate decisions, with a special focus on mechanistic insights and advanced assay strategies. This article delivers actionable guidance for apoptosis and autophagic cell death research.

• Syringin in Translational Oncology: Mechanistic Insights and

  2026-05-24

  Explore how the Syringin natural product advances translational cancer research by elucidating unique mechanisms and optimizing bioactive compound screening. This article provides an in-depth analysis for scientists seeking practical, evidence-based protocols using Syringin.

• Phosbind Acrylamide: Precision Tools for Phosphorylation Ana

  2026-05-23

  Phos binding reagent (Phosbind) acrylamide transforms protein phosphorylation analysis by enabling high-resolution, antibody-free differentiation of phosphorylated and non-phosphorylated proteins. Streamline SDS-PAGE workflows, enhance kinase signaling studies, and troubleshoot common research challenges with this advanced phosphate-binding reagent from APExBIO.

• Gefitinib (ZD1839): Applied Workflows in Advanced Cancer Mod

  2026-05-22

  Gefitinib (ZD1839) unlocks precise EGFR pathway inhibition for complex in vitro models, including patient-specific assembloids that better recapitulate tumor-stroma interactions. This guide delivers actionable protocols, troubleshooting strategies, and experimental insights to maximize reproducibility and translational relevance in cutting-edge cancer research.

• Phosphatidic Acid Drives Decidualization via Src-FAK-RhoA-RO

  2026-05-22

  This study delineates a novel phosphatidic acid (PA)-driven signaling cascade involving Src, FAK, and RhoA/ROCK that orchestrates cytoskeletal remodeling during human endometrial stromal cell decidualization. These findings clarify an independent molecular route for morphological transformation, with implications for infertility research and targeted pathway modulation.

• Mubritinib (TAK 165): Optimizing Mitochondrial Inhibition Wo

  2026-05-21

  Mubritinib (TAK 165) redefines cancer and virology research by precisely targeting mitochondrial complex I, enabling selective cytotoxicity against chemotherapy-resistant AML and KSHV-positive PEL cells. This guide delivers actionable workflow enhancements, troubleshooting strategies, and integrated insights from recent glycolysis-targeting studies to maximize experimental success.

16275 records 1/1085 page Next 12345 下5页 Last page